Drug trial success - anacetrapib did not kill significantly more than placebo!

.
This is great news for Merck regarding their new HDL-boosting-LDL-busting drug Anacetrapib.  Published about a week ago:

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Quote: "The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib."

See also this:

Merck’s Risky Bet on Heart Drugs May Yield Lipitor-Like Success

Interestingly, the company's stock declined by about 5% in November to date.
.